Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Sanofi-Aventis S.A. ADR
(NQ:
SNY
)
48.54
-0.46 (-0.94%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Sanofi-Aventis S.A. ADR
< Previous
1
2
...
19
20
21
22
23
24
25
26
Next >
Acasti Pharma: Bouncing Back With a New Drug Pipeline
January 04, 2022
Picture credit: Louis Reed on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial...
Via
Benzinga
Sanofi Expects Q4 FY21 Vaccine Sales Lower Than Year-Ago, Positive Currency Impact
January 04, 2022
Sanofi SA (NASDAQ: SNY) says the preliminary estimate of currency impact on Q4 sales and business EPS is approximately +1.5% and +2.5%. Also, the Company expects...
Via
Benzinga
Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates
December 31, 2021
Regulatory decisions by the U.S. Food and Drug Administration in December turned out to be mostly positive. Among the treatment options that were greenlighted in the month were...
Via
Benzinga
3 Cathie Wood Stocks To Buy On The Dip
December 25, 2021
Institutional investor Cathie Wood gained popularity after her ETFs generated big gains last year. Wood asserted recently that her stocks are poised for long-term gains. Hence, we think investing in...
Via
Talk Markets
Plague Year Reversal
December 21, 2021
Just in time for Christmas, the market decided to go up today pretty much across the board.
Via
Talk Markets
The Daily Biotech Pulse: Aldeyra Sinks On Dry Eye Disease Readout, Sanofi Goes Shopping, Regulatory Setback For Aquestive, Aridis Touts Pan-Coronavirus Antibody Cocktail
December 21, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CytomX Mid-Phase Study Of ADC In Lung And Head & Neck Cancer Patients...
Via
Benzinga
Sanofi Agrees To Buy US-Based Amunix Pharma For $1B Upfront
December 21, 2021
Sanofi SA (NASDAQ: SNY) will buy an immuno-oncology company, Amunix Pharmaceuticals Inc, for an upfront payment of about $1 billion. Sanofi will also pay Amunix up...
Via
Benzinga
GlaxoSmithKline: Investing In Vaccines
December 19, 2021
GlaxoSmithKline, based in London, is a global healthcare company engaged in the discovery, development, manufacture, and marketing of pharmaceutical and consumer healthcare products. Let's take a look...
Via
Talk Markets
Raising Rates
December 16, 2021
The Bank of England raised its interest rate to 0.25%, setting a pattern for other countries.
Via
Talk Markets
How Will Moderna Stock Weather Omicron? — And Other Questions Clouding 2022
December 16, 2021
Analysts call for a sales and earnings decline in 2022. Can Moderna stave it off?
Via
Investor's Business Daily
Sanofi, Glaxo's COVID-19 Vaccine Candidate Works As Booster, But Data Readout Pushed Back
December 15, 2021
Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline Plc (NYSE: GSK) expect data from late-stage trials of its COVID-19 booster dose in Q1 2022, instead of this year....
Via
Benzinga
The Daily Biotech Pulse: Lilly Raises Guidance, Medtronic Gets FDA Warning Letter, Decision Day For Calliditas, Genenta IPO
December 15, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Vir Biotech Says COVID-19 Antibody Treatment Effective Against Omicron...
Via
Benzinga
3 Stocks That Can Make You Rich in Just a Few Years
December 14, 2021
Investing in the most popular stocks on the Street won't make investors rich in a few years. To accomplish that goal, a contrarian spirit is needed.
Via
InvestorPlace
Sanofi Reveals Late-Stage Data For Fitusiran In Hemophilia Patients
December 14, 2021
Sanofi SA (NASDAQ: SNY) presented data from two Phase 3 studies of fitusiran for the prophylactic treatment with hemophilia A or B, with or without inhibitors....
Via
Benzinga
Are Cannabinoids the Next Frontier of Pharmaceuticals? This Company Thinks So and Wants to Lead the Pack
December 14, 2021
Photo by Michael Longmire on...
Via
Benzinga
Comparing Data: Sanofi Vs. Johnson & Johnson Multiple Myeloma Therapies In Newly Diagnosed Patients
December 13, 2021
Sanofi SA (NASDAQ: SNY) and Johnson & Johnson (NYSE: JNJ) posted new data from their myeloma therapies, Sarclisa and Darzalex, respectively. Data were shared at...
Via
Benzinga
Inflation Surge
December 10, 2021
Today the market failed to brush off inflation fears as it had done later on Thursday as inflation is at a 4 decade high.
Via
Talk Markets
Moderna Stock Dives As Sanofi-Rivaling Flu Shot Underwhelms In First Test
December 10, 2021
The results were generally in line with an older flu shot from Sanofi.
Via
Investor's Business Daily
Moderna Posts Data From Early mRNA Flu Vaccine Study, Pivotal Trial On Its Way
December 10, 2021
Moderna Inc (NASDAQ: MRNA) says that it's on its way to having two mRNA vaccines against different seasonal flu viruses. The Company released the first early data...
Via
Benzinga
Regeneron: Surfing on Covid, With More Under the Surface
December 02, 2021
Regeneron has a method for finding blockbuster drugs, like the Covid drug that powered 2021 REGN stock results, but there's even more to come.
Via
InvestorPlace
Exposures
COVID-19
Is High Pressure Good for Drug Development?
December 02, 2021
Picture credit: National Cancer Institute The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a...
Via
Benzinga
Britain Agrees To New Deals For 114M Additional Moderna, Pfizer/BioNTech COVID-19 Vaccine Doses
December 02, 2021
The British government has agreed on deals to buy 114 million more Pfizer Inc (NYSE: PFE) / BioNTech SE (NASDAQ: BNTX) and Moderna Inc (...
Via
Benzinga
Exposures
COVID-19
The Daily Biotech Pulse: Adcom Backs Merck's Oral COVID-19 Treatment; Regulatory Setbacks For CTI Biopharma, BioXcel; Favorable Ruling For Viatris In Tecfidera Patent Case
December 01, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Adcom Backing For Oral COVID-19 Antiviral Medication Molnupiravir...
Via
Benzinga
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Sanofi Adds Acne Vaccine Candidate Via Origimm Biotechnology Acquisition
December 01, 2021
Sanofi SA (NASDAQ: SNY) has agreed to buy Austrian group Origimm Biotechnology, a move that will add a potential first-in-class vaccine candidate to treat acne...
Via
Benzinga
Baidu Licenses Its Algorithm To Sanofi For mRNA Vaccine, Therapy Development
November 22, 2021
Baidu Inc (NASDAQ: BIDU) has licensed its algorithm for messenger RNA (mRNA) sequence to Sanofi SA (NASDAQ: SNY) for use in designing vaccine and...
Via
Benzinga
The Daily Biotech Pulse: Connect Biopharma Sinks On Eczema Drug Readout, Enanta Pulls Plug On HBV Drug, Clinical Setback For Merck In HIV Trial
November 19, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Connect Biopharma Atopic Dermatitis Treatment Aces Mid-stage Study But Lack...
Via
Benzinga
Pfizer Seeks Covid Boosters For All; But How Long Is The Opportunity?
November 10, 2021
Both vaccine stocks popped after Pfizer asked for booster authorization in all adults.
Via
Investor's Business Daily
Sanofi (SNY) Q3 2021 Earnings Call Transcript
October 29, 2021
SNY earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
The Daily Biotech Pulse: Gilead-Merck Collaborate For Breast Cancer Study, Decision Day For ANI Pharma, Pfizer Gets Canadian Regulatory Nod, 3 IPOs
October 29, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Gilead, Merck to Study Trodelvy-Keytruda Combo For Breast Cancer Gilead, Inc...
Via
Benzinga
Sanofi Raises FY21 Earnings Outlook As Dupixent, Vaccines Boost Q3 Performance
October 28, 2021
Sanofi SA's (NASDAQ: SNY) Q3 sales grew 10.1% Y/Y to €10.4 billion due to solid growth from Dupixent, Vaccines, and Consumer Healthcare. EPS for the...
Via
Benzinga
< Previous
1
2
...
19
20
21
22
23
24
25
26
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.